• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Biosaf Health . . Impact of adjuvants on a recombinant SARS-CoV-2 spike vaccine: Protective efficacy and recall antibody response following homologo

tetano

Editor, Senior Moderator
Biosaf Health


. 2025 Nov 29;8(1):20-30.
doi: 10.1016/j.bsheal.2025.11.004. eCollection 2026 Feb.
Impact of adjuvants on a recombinant SARS-CoV-2 spike vaccine: Protective efficacy and recall antibody response following homologous challenge

Dawei Wang[SUP] 1 [/SUP], Zhendong Pan[SUP] 1 [/SUP], Liangliang Jiang[SUP] 1 [/SUP], Haoran Peng[SUP] 1 [/SUP], Yanhua He[SUP] 1 [/SUP], Yangang Liu[SUP] 1 [/SUP], Xu Zheng[SUP] 1 [/SUP], Cuiling Ding[SUP] 1 [/SUP], Wanda Tang[SUP] 1 [/SUP], Congcong Zhang[SUP] 1 [/SUP], Xiaoyan Zhang[SUP] 2 [/SUP], Jianqing Xu[SUP] 2 [/SUP], Zhongtian Qi[SUP] 1 [/SUP], Ping Zhao[SUP] 1 [/SUP]


Affiliations
Abstract

Immune imprinting, or original antigenic sin, challenges the control of evolving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). How the quantity and quality of pre-existing immunity modulate the recall antibody response upon re-exposure remains poorly understood. We immunized hamsters with a recombinant ancestral spike protein (S-2P) formulated with one of four distinct adjuvants to assess the impact of adjuvant-induced immunity on protective efficacy. Furthermore, we analyzed the modulatory effect of the adjuvant on the potency, breadth, and evolution of antibody responses after homologous viral challenge. We found that vaccination with Montanide ISA720-adjuvanted S-2P (S-2P:ISA720) not only induced higher initial neutralizing antibody titers and conferred stronger protection but also established a pre-existing immune state capable of cross-neutralizing the antigenically distant Omicron BA.1 variant. In contrast, aluminum hydroxide adjuvanted S-2P (S-2P:Al) elicited comparatively lower neutralizing titers and showed no cross-neutralization against BA.1. Following viral challenge, the S-2P:ISA720 group exhibited significant affinity maturation toward conserved epitopes, which markedly enhanced cross-neutralization against BA.1 without increasing neutralizing titers or affinity against the homologous strain or the antigenically related Delta variant. Conversely, the S-2P:Al group mounted a narrow, imprinting-facilitated response, characterized by boosting of strain-specific antibodies without substantial improvement in BA.1 neutralization. These findings suggest that in S-2P:ISA720-immunized animals, high-affinity antibodies mediate epitope masking of immunodominant sites, thereby redirecting responses toward subdominant conserved epitopes with cross-neutralizing potential. In conclusion, our study demonstrates that adjuvants can critically guide recall immune responses toward breadth and affinity maturation, offering a rational strategy for developing next-generation vaccines against SARS-CoV-2 and other variable pathogens.

Keywords: Adjuvant; Antibody affinity; Immune imprinting; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Vaccine.

 
Back
Top Bottom